NTGN - Neon Therapeutics Inc
Previous close
3.07
0 0%
Share volume: 0
Last Updated: Tue 05 May 2020 06:00:00 AM CEST
Biotechnology:
-0.86%
PREVIOUS CLOSE
CHG
CHG%
$3.07
0.00
0.00%
Fundamental analysis
20%
Profitability
25%
Dept financing
7%
Liquidity
34%
Performance
15%
Performance
5 Days
0 0%
1 Month
0 0%
3 Months
0 0%
6 Months
0 0%
1 Year
0 0%
2 Year
0 0%
Key data
Stock price
$3.07
DAY RANGE
$3.07 - $3.07
52 WEEK RANGE
$0.88 - $6.15
52 WEEK CHANGE
-$47.61
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO:
Region: US
Website: https://neontherapeutics.com/
Employees: 71
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Biotechnology
Sector: Health Technology
Region: US
Website: https://neontherapeutics.com/
Employees: 71
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Biotechnology
Sector: Health Technology
BioNTech US, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials. The company was founded by James P. Allison, Edward J. Fritsch, Nir Hacohen, Eric S. Lander, Robert Schreiber, Ton Schumacher and Catherine Wu on October 21, 2013 and is headquartered in Cambridge, MA.
Recent news